I think the tie up with Promega, the move into Therapeutics, and the exosome space in general will see this company substantially re-rated this year.
Sure, a capital raise is likely.....and knowing David Williams he'd probably like to increase his exposure....but even with that occurring, the stock could easily reach a $200mln mkt cap this year.
If you're waiting for the cap raise, you may miss the ride.
I think the tie up with Promega, the move into Therapeutics, and...
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.5¢ |
Change
0.025(4.81%) |
Mkt cap ! $49.69M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 54.5¢ | 53.0¢ | $30.32K | 56.12K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9533 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 1956 | 1 |
View Market Depth
| Last trade - 14.28pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
54.0¢ |
Change
0.025 ( 1.89 %) |
||||
| Open | High | Low | Volume | ||
| 54.0¢ | 54.0¢ | 54.0¢ | 1244 | ||
| Last updated 14.12pm 14/05/2024 ? | |||||
| IIQ (ASX) Chart |